

Atlantic Pharmaceuticals, Inc. Announces Completion of Phase 1 NIH Contract for Technology to Combat Drug Addiction

Atlanta, GA, May 2009 – Atlantic Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that it has completed a Phase 1 Small Business Innovative Research (SBIR) contract for an injectable sustained release depot of buprenorphine indicated for opiate maintenance. The contract was received through the National Institutes of Health (NIH) from the National Institute on Drug Abuse (NIDA)

Atlantic's proprietary injectable delivery technology is a painless injectable solution that forms a sustained release depot upon injection. An injectable depot is less likely to be diverted and abused as is the case with current oral therapies. Additionally, a sustained release depot allows increased compliance to therapy unlike oral therapies, which may be skipped. Adherence to a therapeutic regimen is a cornerstone of successful opiate addiction treatment and recovery.

"We are pleased that the NIH has selected our technology as the basis for this Phase I contract and believe our results will lead to further development of this technology for opiate maintenance", said Anthony Soscia, President of Atlantic Pharmaceuticals. "We look forward to pursuing this product during the next phase of development", he added.

Drug abuse costs American society an estimated \$180 billion a year, including increased health care costs, increased instances of disease transmission such as HIV/AIDS, reduced job productivity, and crime, according to the Office of National Drug Control Policy.

About Atlantic Pharmaceuticals

Atlantic Pharmaceuticals, Inc., is a privately held specialty pharmaceutical company dedicated to the discovery and development of innovative, late stage therapies for substance abuse and pain related conditions and diseases. Our products target therapeutic opportunities utilizing molecules shown to be safe and effective with formulations that are protected by intellectual property. We believe that our approach will lead to improved patient care, reduced healthcare costs and a rapid time to market. For more information, visit the Company's website at www.atlanticpharma.com.

Contact

Anthony Soscia

Phone: 678.638.6170

Atlantic Pharmaceuticals, Inc.

info@atlanticpharma.com